• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Primary outcome of the phase III SYD985.002/TULIP trial comparing vic- trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncManich.pdf
    Size:
    81.60Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Manich, C. S.
    O'Shaughnessy, J.
    Aftimos, P. G.
    van den Tweel, E.
    Oesterholt, M.
    Escriva-de-Romani, S. I.
    Tueux, N. Q.
    Tan, T. J.
    Lim, J. S.
    Ladoire, S.
    Armstrong, Anne C
    Crook, T.
    Stradella, A.
    Bianchi, G.
    Mulder, R.
    Koper, N.
    Turner, N.
    Show allShow less
    Affiliation
    Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d�Hebron, Barcelona, Spain
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background [vic-]Trastuzumab duocarmazine (SYD985, Byondis B.V., NL) is a novel HER2-targeting antibody�drug conjugate comprised of trastuzumab bound to a linker drug containing duocarmycin. TULIP assessed the efficacy of SYD985 in advanced HER2-positive breast cancer. Methods The TULIP trial (NCT03262935) randomly assigned HER2-positive locally advanced or metastatic breast cancer (MBC) patients with ? 2 previous MBC regimens or previous MBC treatment with T-DM1, 2:1 between SYD985 (1.2 mg/kg q three weeks) and physician�s choice (PC) chemotherapy. The primary endpoint was progression-free survival (PFS) by blinded central review. The trial was powered to detect a Hazard Ratio (HR) of 0.65 at the P < 0.05 significance level. Secondary endpoints were investigator-assessed PFS, overall survival (OS), objective response rate (ORR), and health-related quality of life (HRQoL). Results 437 patients from 11 countries were randomized to SYD985 (n=291) or PC (n=146). Median age was 56 years, median number of prior MBC treatments was 4 [range 1-16]. Centrally reviewed median PFS was 7.0 months [95% CI 5.4-7.2] for SYD985 and 4.9 mo [4.0-5.5] for PC (HR 0.64 [0.49-0.84]; p = 0.002). Investigator-assessed PFS was also significantly improved (6.9 mo [6.0-7.2] vs 4.6 mo [4.0-5.6]; HR 0.60 [0.47-0.77]; p < 0.001). In this first analysis of OS the HR was 0.83 [0.62-1.09]; p = 0.153. No significant differences were observed in ORR or HRQoL. The most frequently reported adverse events for SYD985 were conjunctivitis (38.2%), keratitis (38.2%) and fatigue (33.3%), for PC these were diarrhoea (35.8%), nausea (31.4%) and fatigue (29.9%). Interstitial lung disease / pneumonitis was reported for 7.6% (5.2% grade 1-2) of patients treated with SYD985, including two grade 5 events. Adverse events leading to discontinuation (SYD985 35.4%, PC 10.2%) in the SYD985 group were mainly related to eye disorders (20.8%) or respiratory disorders (6.3%). Conclusions Treatment with SYD985 significantly improved PFS in comparison with standard PC and may provide a new treatment option for patients with pre-treated locally advanced or metastatic HER2-positive MBC.
    Citation
    Saura Manich C, O�Shaughnessy J, Aftimos PG, van den Tweel E, Oesterholt M, Escriv�-de-Roman� SI, et al. LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician�s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S1288.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624730
    DOI
    10.1016/j.annonc.2021.08.2088
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.2088
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.2088
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.